Literature DB >> 11200947

Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.

H Uchino1, M Niwa, T Shimizu, K Nishiyama, R Kawamori.   

Abstract

The insulin secretory pattern as a phenotype of type 2 diabetes is an impairment in the rapid, pulsatile secretion of insulin in response to a rise in blood glucose after meal-intake. The restoration of endogenous rapid insulin secretion after oral glucose load was established for the first time by using nateglinide, which is a newly developed insulin secretagogue, in obese patients with type 2 diabetes mellitus. It was clearly demonstrated that with nateglinide, serum insulin levels were quickly raised, and glycemic response curves were almost normalized with the same amount of insulin secretion during 180 min. Therefore, the lack of rapid, pulsatile secretion of insulin in response to glycemic rise after oral glucose load, rather than insulin resistance, is responsible for postprandial glycemic response in obese type 2 diabetes patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11200947     DOI: 10.1507/endocrj.47.639

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

Review 1.  Diabetes in Japan.

Authors:  Takahisa Hirose; Ryuzo Kawamori
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

2.  Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.

Authors:  Kyoko Kudo-Fujimaki; Takahisa Hirose; Tomoaki Yoshihara; Fumihiko Sato; Yuki Someya; Chie Ohmura; Akio Kanazawa; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2013-11-05       Impact factor: 4.232

3.  Characteristics associated with elevated 1-h plasma glucose levels during a 75-g oral glucose tolerance test in non-obese Japanese men.

Authors:  Motonori Sato; Yoshifumi Tamura; Yuki Someya; Kageumi Takeno; Hideyoshi Kaga; Satoshi Kadowaki; Daisuke Sugimoto; Saori Kakehi; Takashi Funayama; Yasuhiko Furukawa; Ruriko Suzuki; Takashi Nakagata; Miho Nishitani-Yokoyama; Kazunori Shimada; Hiroyuki Daida; Shigeki Aoki; Hiroaki Sato; Ryuzo Kawamori; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2020-03-30       Impact factor: 4.232

4.  Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).

Authors:  Yuichi Terawaki; Chikayo Iwaya; Takashi Nomiyama; Dai Shimono; Tsuyoshi Horikawa; Yuki Fujimura-Tanaka; Toru Shigeoka; Nobuya Hamanoue; Ryoko Motonaga; Makito Tanabe; Toshihiko Yanase; Daiji Kawanami
Journal:  Diabetol Int       Date:  2020-02-14

5.  Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.

Authors:  Masumi Tanimoto; Akio Kanazawa; Takahisa Hirose; Tomoaki Yoshihara; Saeko Kobayashi-Kimura; Risa Nakanishi; Yuka Tosaka; Ruri Sasaki-Omote; Kyoko Kudo-Fujimaki; Koji Komiya; Fuki Ikeda; Yuki Someya; Tomoya Mita; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2015-03-15       Impact factor: 4.232

6.  Ingestion of an exogenous ketone monoester improves the glycemic response during oral glucose tolerance test in individuals with impaired glucose tolerance: A cross-over randomized trial.

Authors:  Takashi Nakagata; Yoshifumi Tamura; Hideyoshi Kaga; Motonori Sato; Nozomu Yamasaki; Yuki Someya; Satoshi Kadowaki; Daisuke Sugimoto; Hiroaki Satoh; Ryuzo Kawamori; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2020-11-01       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.